Medivir Overview
- Year Founded
-
1988
- Status
-
Public
- Employees
-
10
- Stock Symbol
-
MVIR
- Investments
-
5
- Share Price
-
$0.12
- (As of Friday Closing)
Medivir General Information
Description
Medivir AB develops therapies targeting diseases with high unmet medical need. The group's drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Its two programs are fostrox, designed to target liver cancer cells while minimizing side effects selectively, and MIV-711, aimed at treating Osteogenesis Imperfecta (Brittle bone disease) and Legg-Calve-Perthes disease (Perthes disease). It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. It also has four out-licensed projects, Xerclear, MIV-701, MBLI/MET-X, and remetinostat. Geographic revenue is generated from Europe and other regions.
Contact Information
Website
www.medivir.comCorporate Office
- Lunastigen 5
- 2nd Floor, Box 1086
- 141 22 Huddinge
- Sweden
Corporate Office
- Lunastigen 5
- 2nd Floor, Box 1086
- 141 22 Huddinge
- Sweden
Medivir Stock Performance
As of 13-Nov-2026, Medivir’s stock price is $0.12. Its current market cap is $72M with 624M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.12 | $0.12 | $0.04 - $0.31 | $72M | 624M | 1.83M | -$0.03 |
Medivir Financials Summary
As of 30-Sep-2026, Medivir has a trailing 12-month revenue of $905K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 76,897 | 17,419 | 20,539 | 23,685 |
| Revenue | 905 | 866 | 329 | 718 |
| EBITDA | (6,151) | (6,058) | (11,335) | (8,062) |
| Net Income | (9,440) | (9,608) | (11,660) | (8,404) |
| Total Assets | 32,643 | 21,430 | 15,642 | 28,809 |
| Total Debt | 0 | 912 | 1,003 | 1,354 |
Medivir Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Medivir Comparisons
Industry
Financing
Details
Medivir Competitors (9)
One of Medivir’s 9 competitors is Ability Pharma, a Private Equity-Backed company based in Cerdanyola, Spain.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| Indivior | Corporate Backed or Acquired | North Chesterfield, VA | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| BioInvent International | Formerly VC-backed | Lund, Sweden | ||||
| Ultragenyx Pharmaceutical | Formerly VC-backed | Novato, CA |
Medivir Patents
Medivir Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026185278-A1 | N-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4- methyl-piperazin-1-yl)thiazol-4-yl]-benzamide for use in the treatment of osteogenesis imperfecta | Pending | 05-Mar-2025 | ||
| AU-2025233872-A1 | Treatment of bone loss | Pending | 06-Mar-2024 | ||
| EP-4613273-A1 | Treatment of bone loss | Inactive | 06-Mar-2024 | ||
| WO-2025186343-A1 | Treatment of bone loss | Pending | 06-Mar-2024 | ||
| WO-2025186343-A8 | Treatment of bone loss | Pending | 06-Mar-2024 | A61K31/496 |
Medivir Signals
Medivir Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Medivir Investments & Acquisitions (5)
Medivir’s most recent deal was a Corporate Asset Purchase with Tetralogic Pharmaceuticals (Portfolio of Clinical Stage Oncology Programs) for . The deal was made on 29-Dec-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tetralogic Pharmaceuticals (Portfolio of Clinical Stage Oncology Programs) | 29-Dec-2016 | Corporate Asset Purchase | Other Healthcare Technology Systems | ||
| Novadex Pharmaceuticals (Preclinical Research Stage Assets in Umea, Sweden) | 05-Sep-2012 | Corporate Asset Purchase | Buildings and Property | ||
| BioPhausia | 11-Jun-2011 | Merger/Acquisition | Distributors (Healthcare) | ||
| Presidio Pharmaceuticals | 09-Jul-2009 | Early Stage VC | Drug Discovery | ||
| Mimetrix | 27-Mar-2000 | Merger/Acquisition | Drug Discovery |
Medivir ESG
Risk Overview
Risk Rating
Updated November, 30, 2024
38.02 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Biotechnology
Subindustry
of 434
Rank
Percentile
Medivir Exits (2)
Medivir’s most recent exit was on 11-Jun-2011 from BioPhausia. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| BioPhausia | 11-Jun-2011 | Completed |
|
||
| Presidio Pharmaceuticals | 09-Jul-2009 | Early Stage VC | Completed |
|
Medivir Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Medivir Personal | Huddinge, Sweden | 2000 |
Medivir FAQs
-
When was Medivir founded?
Medivir was founded in 1988.
-
Where is Medivir headquartered?
Medivir is headquartered in Huddinge, Sweden.
-
What is the size of Medivir?
Medivir has 10 total employees.
-
What industry is Medivir in?
Medivir’s primary industry is Drug Discovery.
-
Is Medivir a private or public company?
Medivir is a Public company.
-
What is Medivir’s stock symbol?
The ticker symbol for Medivir is MVIR.
-
What is the current stock price of Medivir?
As of 13-Nov-2026 the stock price of Medivir is $0.12.
-
What is the current market cap of Medivir?
The current market capitalization of Medivir is $72M.
-
What is Medivir’s current revenue?
The trailing twelve month revenue for Medivir is $905K.
-
Who are Medivir’s competitors?
Ability Pharma, Indivior, Bristol-Myers Squibb, BioInvent International, and Ultragenyx Pharmaceutical are some of the 9 competitors of Medivir.
-
What is Medivir’s annual earnings per share (EPS)?
Medivir’s EPS for 12 months was -$0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process